Fredrik Piehl

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1595060/publications.pdf

Version: 2024-02-01

280 papers	21,363 citations	16437 64 h-index	12258 133 g-index
288 all docs	288 docs citations	288 times ranked	25612 citing authors

#	Article	IF	Citations
1	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature, 2011, 476, 214-219.	13.7	2,400
2	Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nature Genetics, 2013, 45, 1353-1360.	9.4	1,213
3	Neurofilaments as biomarkers in neurological disorders. Nature Reviews Neurology, 2018, 14, 577-589.	4.9	1,177
4	Multiple sclerosis. Nature Reviews Disease Primers, 2018, 4, 43.	18.1	767
5	Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science, 2019, 365, .	6.0	710
6	Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium. Biological Psychiatry, 2018, 84, 644-654.	0.7	627
7	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. JAMA Neurology, 2019, 76, 1035.	4.5	455
8	Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis. Cell, 2018, 175, 85-100.e23.	13.5	350
9	Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. JAMA Neurology, 2020, 77, 184.	4.5	342
10	Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology, 2017, 89, 2230-2237.	1.5	307
11	Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Annals of Neurology, 2011, 69, 83-89.	2.8	295
12	Neuroprotection by Encephalomyelitis: Rescue of Mechanically Injured Neurons and Neurotrophin Production by CNS-Infiltrating T and Natural Killer Cells. Journal of Neuroscience, 2000, 20, 5283-5291.	1.7	293
13	Rituximab in multiple sclerosis. Neurology, 2016, 87, 2074-2081.	1.5	278
14	MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. Nature Genetics, 2005, 37, 486-494.	9.4	276
15	Risk factors for amyotrophic lateral sclerosis. Clinical Epidemiology, 2015, 7, 181.	1.5	272
16	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Multiple Sclerosis Journal, 2015, 21, 1013-1024.	1.4	249
17	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurology, The, 2018, 17, 405-415.	4.9	238
18	From The Cover: A role for MHC class I molecules in synaptic plasticity and regeneration of neurons after axotomy. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 17843-17848.	3.3	233

#	Article	IF	Citations
19	Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurology, The, 2020, 19, 307-316.	4.9	219
20	Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Multiple Sclerosis Journal, 2011, 17, 335-343.	1.4	213
21	Systemic Inflammation in Progressive Multiple Sclerosis Involves Follicular T-Helper, Th17- and Activated B-Cells and Correlates with Progression. PLoS ONE, 2013, 8, e57820.	1.1	213
22	Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurology, The, 2022, 21, 246-257.	4.9	210
23	T Cell Ig- and Mucin-Domain-Containing Molecule-3 (TIM-3) and TIM-1 Molecules Are Differentially Expressed on Human Th1 and Th2 Cells and in Cerebrospinal Fluid-Derived Mononuclear Cells in Multiple Sclerosis. Journal of Immunology, 2004, 172, 7169-7176.	0.4	200
24	Phenotypes and Predictors of Pain Following Traumatic Spinal Cord Injury: A Prospective Study. Journal of Pain, 2014, 15, 40-48.	0.7	194
25	Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology, 2016, 79, 950-958.	2.8	190
26	GDNF mRNA in Schwann cells and DRG satellite cells after chronic sciatic nerve injury. NeuroReport, 1996, 7, 857-860.	0.6	187
27	Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis. JAMA Neurology, 2018, 75, 320.	4.5	155
28	Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. Multiple Sclerosis Journal, 2018, 24, 1046-1054.	1.4	149
29	Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain, 2015, 138, 918-931.	3.7	147
30	DNA methylation as a mediator of HLA-DRB1*15:01 and a protective variant in multiple sclerosis. Nature Communications, 2018, 9, 2397.	5.8	147
31	GM-CSF and CXCR4 define a T helper cell signature in multiple sclerosis. Nature Medicine, 2019, 25, 1290-1300.	15.2	140
32	Multiple sclerosis-associated IL2RA polymorphism controls GM-CSF production in human TH cells. Nature Communications, 2014, 5, 5056.	5.8	137
33	Characterization of the mouse Men1 gene and its expression during development. Oncogene, 1998, 17, 2485-2493.	2.6	133
34	A Serum Protein Biomarker Panel Improves Outcome Prediction in Human Traumatic Brain Injury. Journal of Neurotrauma, 2019, 36, 2850-2862.	1.7	129
35	Confounding effect of blood volume and body mass index on blood neurofilament light chain levels. Annals of Clinical and Translational Neurology, 2020, 7, 139-143.	1.7	126
36	Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsingâ€remitting multiple sclerosis. Journal of Neurochemistry, 2017, 141, 296-304.	2.1	124

#	Article	IF	Citations
37	Comparative Assessment of the Prognostic Value of Biomarkers in Traumatic Brain Injury Reveals an Independent Role for Serum Levels of Neurofilament Light. PLoS ONE, 2015, 10, e0132177.	1.1	114
38	Calcitonin Gene-Related Peptide in the Brain, Spinal Cord, and Some Peripheral Systems. Annals of the New York Academy of Sciences, 1992, 657, 119-134.	1.8	113
39	Inflammation-related plasma and CSF biomarkers for multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 12952-12960.	3.3	102
40	Increased Brain-Derived Neurotrophic Factor Expression in White Blood Cells of Relapsing-Remitting Multiple Sclerosis Patients. Scandinavian Journal of Immunology, 2003, 57, 493-497.	1.3	98
41	A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Multiple Sclerosis Journal, 2011, 17, 708-719.	1.4	98
42	Induction of VEGF and VEGF receptors in the spinal cord after mechanical spinal injury and prostaglandin administration. European Journal of Neuroscience, 2000, 12, 3675-3686.	1.2	97
43	Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes. Nature Communications, 2019, 10, 3081.	5.8	97
44	Differential regulation of trophic factor receptor mRNAs in spinal motoneurons after sciatic nerve transection and ventral root avulsion in the rat. Journal of Comparative Neurology, 2000, 426, 587-601.	0.9	96
45	Peripheral nerve section induces increased levels of calcitonin gene-related peptide (CGRP)-like immunoreactivity in axotomized motoneurons. Experimental Brain Research, 1990, 79, 212-6.	0.7	93
46	Menin Interacts Directly with the Homeobox-Containing Protein Pem. Biochemical and Biophysical Research Communications, 2001, 286, 426-431.	1.0	92
47	Circulating miR-150 in CSF is a novel candidate biomarker for multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e219.	3.1	92
48	Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis. JAMA Neurology, 2021, 78, 1197.	4.5	90
49	The autoimmune spectrum of myasthenia gravis: a Swedish populationâ€based study. Journal of Internal Medicine, 2015, 277, 594-604.	2.7	89
50	B cell alterations during BAFF inhibition with belimumab in SLE. EBioMedicine, 2019, 40, 517-527.	2.7	88
51	Blood neurofilament light levels segregate treatment effects in multiple sclerosis. Neurology, 2020, 94, e1201-e1212.	1.5	88
52	Profiling of CD4+ T Cells with Epigenetic Immune Lineage Analysis. Journal of Immunology, 2011, 186, 92-102.	0.4	86
53	Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies. Multiple Sclerosis Journal, 2018, 24, 1224-1233.	1.4	86
54	Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. Annals of Neurology, 2020, 87, 688-699.	2.8	86

#	Article	IF	Citations
55	The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatmentâ€sensitive biomarkers. European Journal of Neurology, 2009, 16, 528-536.	1.7	84
56	Expression of NMDA Receptor mRNAs in Rat Motoneurons is Down-regulated after Axotomy. European Journal of Neuroscience, 1995, 7, 2101-2110.	1.2	82
57	Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 62-71.	1.4	81
58	Expression of GAP-43 mRNA in the adult mammalian spinal cord under normal conditions and after different types of lesions, with special reference to motoneurons. Experimental Brain Research, 1992, 91, 284-95.	0.7	77
59	Expression of MHC class I heavy chain and Î²2-microglobulin in rat brainstem motoneurons and nigral dopaminergic neurons. Journal of Neuroimmunology, 1999, 101, 76-86.	1.1	76
60	Low vascular endothelial growth factor and interleukin-8 in cerebrospinal fluid of suicide attempters. Translational Psychiatry, 2012, 2, e196-e196.	2.4	75
61	Regulated Extracellular Choline Acetyltransferase Activityâ€" The Plausible Missing Link of the Distant Action of Acetylcholine in the Cholinergic Anti-Inflammatory Pathway. PLoS ONE, 2013, 8, e65936.	1.1	72
62	Fatigue and depression in multiple sclerosis: pharmacological and non-pharmacological interventions. Acta Neurologica Scandinavica, 2016, 134, 47-54.	1.0	72
63	Intense Inflammation and Nerve Damage in Early Multiple Sclerosis Subsides at Older Age: A Reflection by Cerebrospinal Fluid Biomarkers. PLoS ONE, 2013, 8, e63172.	1.1	69
64	Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e191.	3.1	69
65	High interleukin-6 and impulsivity: determining the role of endophenotypes in attempted suicide. Translational Psychiatry, 2014, 4, e470-e470.	2.4	68
66	Calcitonin Gene-related Peptide (CGRP)-like Immunoreactivity and CGRP mRNA in Rat Spinal Cord Motoneurons after Different Types of Lesions. European Journal of Neuroscience, 1991, 3, 737-757.	1.2	67
67	Expression of insulin-like growth factors and corresponding binding proteins (IGFBP 1-6) in rat spinal cord and peripheral nerve after axonal injuries. , 1998, 400, 57-72.		67
68	Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs. Multiple Sclerosis Journal, 2013, 19, 765-774.	1.4	66
69	Fibroblast Growth Factors Regulate Calcitonin Gene-related Peptide mRNA Expression in Rat Motoneurons after Lesion and in Culture. European Journal of Neuroscience, 1995, 7, 1739-1750.	1.2	65
70	Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis. JAMA Neurology, 2020, 77, 974.	4.5	65
71	Increased trkB mRNA expression by axotomized motoneurones. NeuroReport, 1994, 5, 697-700.	0.6	64
72	Expression of neuropeptides and neuropeptide mRNAs in spinal cord after axotomy in the rat, with special reference to motoneurons and galanin. Experimental Brain Research, 1993, 93, 450-61.	0.7	63

#	Article	IF	Citations
73	GAP-43, aFGF, CCK and Î±- and Î²-CGRP in Rat Spinal Motoneurons Subjected to Axotomy and/or Dorsal Root Severance. European Journal of Neuroscience, 1993, 5, 1321-1333.	1.2	61
74	Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis. Neurology, 2020, 94, e2457-e2467.	1.5	61
75	High-intensity resistance training in multiple sclerosis â€" An exploratory study of effects on immune markers in blood and cerebrospinal fluid, and on mood, fatigue, health-related quality of life, muscle strength, walking and cognition. Journal of the Neurological Sciences, 2016, 362, 251-257.	0.3	59
76	Identification of MS-specific serum miRNAs in an international multicenter study. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e491.	3.1	59
77	Neurological manifestations of coronavirus infections â€" a systematic review. Annals of Clinical and Translational Neurology, 2020, 7, 2057-2071.	1.7	59
78	Rituximab, MS, and pregnancy. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	59
79	Prominent Expression of bFGF in Dorsal Root Ganglia after Axotomy. European Journal of Neuroscience, 1995, 7, 2458-2468.	1.2	58
80	Swedish natalizumab (Tysabri) multiple sclerosis surveillance study. Neurological Sciences, 2011, 31, 289-293.	0.9	58
81	Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society. Acta Neurologica Scandinavica, 2017, 135, 17-24.	1.0	57
82	Autologous hematopoietic stem cell transplantation in neuromyelitis optica: A registry study of the EBMT Autoimmune Diseases Working Party. Multiple Sclerosis Journal, 2015, 21, 189-197.	1.4	56
83	Cerebrospinal fluid kynurenines in multiple sclerosis; relation to disease course and neurocognitive symptoms. Brain, Behavior, and Immunity, 2016, 51, 47-55.	2.0	56
84	Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab. Neuromuscular Disorders, 2017, 27, 565-568.	0.3	56
85	International consensus on quality standards for brain health-focused care in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1809-1818.	1.4	55
86	Characterization of the human synaptogyrin gene family. Human Genetics, 1998, 103, 131-141.	1.8	54
87	Expression of nonclassical MHC class I (RT1-U) in certain neuronal populations of the central nervous system. European Journal of Neuroscience, 1999, 11, 4468-4472.	1.2	54
88	Increase in Î±-CGRP and GAP-43 in aged motoneurons: A study of peptides, growth factors, and ChAT mRNA in the lumbar spinal cord of senescent rats with symptoms of hindlimb incapacities. Journal of Comparative Neurology, 1995, 359, 69-89.	0.9	53
89	Changes in the mRNA expression pattern, with special reference to calcitonin gene-related peptide, after axonal injuries in rat motoneurons depends on age and type of injury. Experimental Brain Research, 1998, 119, 191-204.	0.7	53
90	Genome-Wide Association Study of Late-Onset Myasthenia Gravis: Confirmation of TNFRSF11A and Identification of ZBTB10 and Three Distinct HLA Associations. Molecular Medicine, 2015, 21, 769-781.	1.9	52

#	Article	IF	Citations
91	Complement Component C3 and Butyrylcholinesterase Activity Are Associated with Neurodegeneration and Clinical Disability in Multiple Sclerosis. PLoS ONE, 2015, 10, e0122048.	1.1	52
92	Differential Expression of Neurotrophic Factors and Inflammatory Cytokines by Myelin Basic Protein-Specific and Other Recruited T Cells Infiltrating the Central Nervous System during Experimental Autoimmune Encephalomyelitis. Scandinavian Journal of Immunology, 2002, 55, 264-273.	1.3	51
93	A changing treatment landscape for multiple sclerosis: challenges and opportunities. Journal of Internal Medicine, 2014, 275, 364-381.	2.7	50
94	Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis. Journal of Neuroimmunology, 2000, 103, 202-210.	1.1	48
95	Neuroinflammation in the rat - CNS cells and their role in the regulation of immune reactions. Immunological Reviews, 2001, 184, 212-225.	2.8	48
96	Functional variability in butyrylcholinesterase activity regulates intrathecal cytokine and astroglial biomarker profiles in patients with Alzheimer's disease. Neurobiology of Aging, 2013, 34, 2465-2481.	1.5	48
97	Neurodegeneration and glial activation patterns after mechanical nerve injury are differentially regulated by non-MHC genes in congenic inbred rat strains. Journal of Comparative Neurology, 2001, 431, 75-87.	0.9	47
98	Cognitive Impairment Has a Strong Relation to Nonsomatic Symptoms of Depression in Relapsing-Remitting Multiple Sclerosis. Archives of Clinical Neuropsychology, 2013, 28, 144-155.	0.3	46
99	Strain influences on inflammatory pathway activation, cell infiltration and complement cascade after traumatic brain injury in the rat. Brain, Behavior, and Immunity, 2013, 27, 109-122.	2.0	46
100	Successful combined targeting of B- and plasma cells in treatment refractory anti-NMDAR encephalitis. Journal of Neuroimmunology, 2017, 312, 15-18.	1.1	46
101	Polygenic link between blood lipids and amyotrophic lateral sclerosis. Neurobiology of Aging, 2018, 67, 202.e1-202.e6.	1.5	46
102	Rituximab treatment for multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 137-152.	1.4	46
103	Restricted Expression Pattern ofvegf-din the Adult and Fetal Mouse: High Expression in the Embryonic Lung. Biochemical and Biophysical Research Communications, 1999, 257, 891-894.	1.0	45
104	Combining evidence from four immune cell types identifies DNA methylation patterns that implicate functionally distinct pathways during Multiple Sclerosis progression. EBioMedicine, 2019, 43, 411-423.	2.7	45
105	Current and emerging diseaseâ€modulatory therapies and treatment targets for multiple sclerosis. Journal of Internal Medicine, 2021, 289, 771-791.	2.7	45
106	Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial. Lancet Neurology, The, 2022, 21, 693-703.	4.9	45
107	CSF GABA is reduced in first-episode psychosis and associates to symptom severity. Molecular Psychiatry, 2018, 23, 1244-1250.	4.1	44
108	Comparative effectiveness of rituximab relative to IFN-Î² or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Multiple Sclerosis Journal, 2018, 24, 1087-1095.	1.4	44

#	Article	IF	Citations
109	Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity. Multiple Sclerosis and Related Disorders, 2020, 37, 101468.	0.9	44
110	Regulation of laminin-associated integrin subunit mRNAs in rat spinal motoneurons during postnatal development and after axonal injury. Journal of Comparative Neurology, 2000, 428, 294-304.	0.9	43
111	Hexosylceramides as intrathecal markers of worsening disability in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1271-1279.	1.4	43
112	The Temporal Retinal Nerve Fiber Layer Thickness Is the Most Important Optical Coherence Tomography Estimate in Multiple Sclerosis. Frontiers in Neurology, 2017, 8, 675.	1.1	43
113	Prior poliomyelitisâ€"Ivlg treatment reduces proinflammatory cytokine production. Journal of Neuroimmunology, 2004, 150, 139-144.	1.1	42
114	Rituximab in paediatric onset multiple sclerosis: a case series. Journal of Neurology, 2016, 263, 322-326.	1.8	42
115	Validation of Rapid Magnetic Resonance Myelin Imaging in Multiple Sclerosis. Annals of Neurology, 2020, 87, 710-724.	2.8	42
116	Calcitonin gene-related peptide-like immunoreactivity in motoneuron pools innervating different hind limb muscles in the rat. Experimental Brain Research, 1993, 96, 291-303.	0.7	41
117	Cross Talk in HEK293 Cells Between Nrf2, HIF, and NF-ÎºB Activities upon Challenges with Redox Therapeutics Characterized with Single-Cell Resolution. Antioxidants and Redox Signaling, 2017, 26, 229-246.	2.5	41
118	Impact of genetic risk loci for multiple sclerosis on expression of proximal genes in patients. Human Molecular Genetics, 2018, 27, 912-928.	1.4	41
119	Discrete Gene Loci Regulate Neurodegeneration, Lymphocyte Infiltration, and Major Histocompatibility Complex Class II Expression in the CNS. Journal of Neuroscience, 2003, 23, 9817-9823.	1.7	40
120	The peptidergic motoneurone. NeuroReport, 1993, 4, 849-856.	0.6	39
121	Expression of theBCL6Gene in the Pre- and Postnatal Mouse. Biochemical and Biophysical Research Communications, 1998, 247, 357-360.	1.0	39
122	Non-MHC gene regulation of nerve root injury induced spinal cord inflammation and neuron death. Journal of Neuroimmunology, 1999, 101, 87-97.	1.1	38
123	Incidence of osmotic demyelination syndrome in Sweden: A nationwide study. Acta Neurologica Scandinavica, 2019, 140, 342-349.	1.0	38
124	Differential Expression of the Chemokine Receptors CX‹sub›3‹/sub›CR1 and CCR1 by Microglia and Macrophages in Myelinâ€Oligodendrocyteâ€Glycoproteinâ€Induced Experimental Autoimmune Encephalomyelitis. Brain Pathology, 2003, 13, 617-629.	2.1	37
125	Properties of motoneurons underlying their regenerative capacity after axon lesions in the ventral funiculus or at the surface of the spinal cord. Brain Research Reviews, 2002, 40, 309-316.	9.1	36
126	Decreased Expression of VEGF-A in Rat Experimental Autoimmune Encephalomyelitis and in Cerebrospinal Fluid Mononuclear Cells from Patients with Multiple Sclerosis. Scandinavian Journal of Immunology, 2006, 64, 609-622.	1.3	36

#	Article	IF	Citations
127	Neurodegenerative and psychiatric diseases among families with amyotrophic lateral sclerosis. Neurology, 2017, 89, 578-585.	1.5	36
128	Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis. IScience, 2021, 24, 103078.	1.9	36
129	Infections in patients with multiple sclerosis: A national cohort study in Sweden. Multiple Sclerosis and Related Disorders, 2020, 45, 102420.	0.9	34
130	The Expression of VEGF-A Is Down Regulated in Peripheral Blood Mononuclear Cells of Patients with Secondary Progressive Multiple Sclerosis. PLoS ONE, 2011, 6, e19138.	1.1	33
131	Hypermethylation of MIR21 in CD4+ T cells from patients with relapsing-remitting multiple sclerosis associates with lower miRNA-21 levels and concomitant up-regulation of its target genes. Multiple Sclerosis Journal, 2018, 24, 1288-1300.	1.4	33
132	Genetics of rat neuroinflammation. Journal of Neuroimmunology, 2000, 107, 191-200.	1.1	32
133	Genetic analysis of neuropathic pain-like behavior following peripheral nerve injury suggests a role of the major histocompatibility complex in development of allodynia. Pain, 2008, 136, 313-319.	2.0	32
134	Genetic regulation of microglia activation, complement expression, and neurodegeneration in a rat model of traumatic brain injury. Experimental Brain Research, 2010, 205, 103-114.	0.7	32
135	Tryptophan Metabolism Along the Kynurenine Pathway Downstream of Tollâ€like Receptor Stimulation in Peripheral Monocytes. Scandinavian Journal of Immunology, 2016, 84, 262-271.	1.3	32
136	Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 85-93.	1.4	32
137	Regulatory effects of trophic factors on expression and distribution of CGRP and GAP-43 in rat motoneurons. , 1998, 51, 1.		31
138	Gsta4 controls apoptosis of differentiating adult oligodendrocytes during homeostasis and remyelination via the mitochondria-associated Fas-Casp8-Bid-axis. Nature Communications, 2020, 11, 4071.	5.8	31
139	Enlarged perivascular spaces in multiple sclerosis on magnetic resonance imaging: a systematic review and meta-analysis. Journal of Neurology, 2020, 267, 3199-3212.	1.8	31
140	Fluid proteomics of CSF and serum reveal important neuroinflammatory proteins in bloodâ€“brain barrier disruption and outcome prediction following severe traumatic brain injury: a prospective, observational study. Critical Care, 2021, 25, 103.	2.5	31
141	Expression of T cell immunoglobulin- and mucin-domain-containing molecules-1 and -3 (TIM-1 and -3) in the rat nervous and immune systems. Journal of Neuroimmunology, 2005, 164, 93-104.	1.1	30
142	Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment. Multiple Sclerosis Journal, 2018, 24, 472-480.	1.4	30
143	Upregulation of VEGF-A Without Angiogenesis in a Mouse Model of Dilated Cardiomyopathy Caused by Mitochondrial Dysfunction. Journal of Histochemistry and Cytochemistry, 2002, 50, 935-944.	1.3	28
144	Brain Age Prediction Reveals Aberrant Brain White Matter in Schizophrenia and Bipolar Disorder: A Multisample Diffusion Tensor Imaging Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2020, 5, 1095-1103.	1.1	28

#	Article	IF	Citations
145	A novel, robust method for quantification of multiple kynurenine pathway metabolites in the cerebrospinal fluid. Bioanalysis, 2020, 12, 379-392.	0.6	28
146	Patient-Reported Symptom Severity in a Nationwide Myasthenia Gravis Cohort. Neurology, 2021, 97, .	1.5	28
147	VAMPâ€1 and VAMPâ€2 gene expression in rat spinal motoneurones: differential regulation after neuronal injury. European Journal of Neuroscience, 1998, 10, 301-316.	1.2	27
148	Population-based incidence and clinical characteristics of idiopathic intracranial hypertension. Acta Neurologica Scandinavica, 2017, 136, 427-433.	1.0	27
149	Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology, 2019, 26, 1060-1067.	1.7	27
150	Concomitant autoimmunity in myasthenia gravis â€" Lack of association with IgA deficiency. Journal of Neuroimmunology, 2011, 236, 118-122.	1.1	26
151	Naturally Occurring Variation in the Glutathione-S-Transferase 4 Gene Determines Neurodegeneration After Traumatic Brain Injury. Antioxidants and Redox Signaling, 2013, 18, 784-794.	2.5	25
152	P300 amplitude and response speed relate to preserved cognitive function in relapsingâ€"remitting multiple sclerosis. Clinical Neurophysiology, 2015, 126, 689-697.	0.7	25
153	Depression and fatigue in multiple sclerosis: Relation to exposure to violence and cerebrospinal fluid immunomarkers. Psychoneuroendocrinology, 2018, 89, 53-58.	1.3	25
154	Age-dependent variation of genotypes in MHC II transactivator gene (CIITA) in controls and association to type 1 diabetes. Genes and Immunity, 2012, 13, 632-640.	2.2	24
155	Genetic and sex influence on neuropathic painâ€like behaviour after spinal cord injury in the rat. European Journal of Pain, 2012, 16, 1368-1377.	1.4	24
156	NR1H3 p.Arg415Gln Is Not Associated to Multiple Sclerosis Risk. Neuron, 2016, 92, 333-335.	3.8	24
157	Neuronal methylome reveals CREB-associated neuro-axonal impairment in multiple sclerosis. Clinical Epigenetics, 2019, 11, 86.	1.8	24
158	Complex Autoantibody Responses Occur following Moderate to Severe Traumatic Brain Injury. Journal of Immunology, 2021, 207, 90-100.	0.4	24
159	Differential subcellular localization of SNAP-25a and SNAP-25b RNA transcripts in spinal motoneurons and plasticity in expression after nerve injury. Molecular Brain Research, 1996, 37, 49-62.	2.5	23
160	Expression of the VEGF-Related Factor Gene in Pre- and Postnatal Mouse. Biochemical and Biophysical Research Communications, 1996, 220, 147-152.	1.0	23
161	Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study. European Journal of Clinical Pharmacology, 2018, 74, 219-226.	0.8	23
162	Expression of insulin-like growth factors and corresponding binding proteins (IGFBP 1-6) in rat spinal cord and peripheral nerve after axonal injuries. Journal of Comparative Neurology, 1998, 400, 57-72.	0.9	23

#	Article	IF	Citations
163	Expression and chromosomal localization of the Requiem gene. Mammalian Genome, 1998, 9, 660-665.	1.0	22
164	Different epigenetic clocks reflect distinct pathophysiological features of multiple sclerosis. Epigenomics, 2019, 11, 1429-1439.	1.0	22
165	Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	22
166	Successful autologous haematopoietic stem cell transplantation for refractory myasthenia gravis â€“ a case report. Neuromuscular Disorders, 2017, 27, 90-93.	0.3	21
167	Creatinine and C-reactive protein in amyotrophic lateral sclerosis, multiple sclerosis and Parkinsonâ€™s disease. Brain Communications, 2020, 2, fcaa152.	1.5	21
168	Both MHC and non-MHC genes regulate inflammation and T-cell response after traumatic brain injury. Brain, Behavior, and Immunity, 2011, 25, 981-990.	2.0	20
169	Novel genetic loci associated HLA-B*08:01 positive myasthenia gravis. Journal of Autoimmunity, 2018, 88, 43-49.	3.0	20
170	Increased number of monocytes and plasma levels of <scp>MCP</scp>â€1 and <scp>YKL</scp>â€40 in firstâ€episode psychosis. Acta Psychiatrica Scandinavica, 2018, 138, 432-440.	2.2	20
171	Age-dependent effects on the treatment response of natalizumab in MS patients. Multiple Sclerosis Journal, 2015, 21, 48-56.	1.4	19
172	Complement Receptor 2 is increased in cerebrospinal fluid of multiple sclerosis patients and regulates C3 function. Clinical Immunology, 2016, 166-167, 89-95.	1.4	19
173	Dynamics of cerebrospinal fluid levels of matrix metalloproteinases in human traumatic brain injury. Scientific Reports, 2020, 10, 18075.	1.6	19
174	Screening for pathogenic neuronal autoantibodies in serum and CSF of patients with first-episode psychosis. Translational Psychiatry, 2021, 11, 566.	2.4	19
175	trkC-like Immunoreactivity in the Primate Descending Serotoninergic System. European Journal of Neuroscience, 1994, 6, 230-236.	1.2	18
176	Expression of LAZ3/BCL6 in follicular center (FC) B cells of reactive lymph nodes and FC-derived non-Hodgkin lymphomas. Leukemia, 1997, 11, 594-598.	3.3	18
177	Genetics of autoimmune neuroinflammation. Current Opinion in Immunology, 2006, 18, 643-649.	2.4	18
178	Vra4 Congenic Rats with Allelic Differences in the Class II Transactivator Gene Display Altered Susceptibility to Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2008, 180, 3289-3296.	0.4	18
179	High levels of 15-oxygenated steroids in circulation of patients with multiple sclerosis: fact or fiction?. Journal of Lipid Research, 2011, 52, 170-174.	2.0	18
180	Multiple sclerosis risk genotypes correlate with an elevated cerebrospinal fluid level of the suggested prognostic marker CXCL13. Multiple Sclerosis Journal, 2013, 19, 863-870.	1.4	18

#	Article	IF	Citations
181	Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study. Journal of the Neurological Sciences, 2019, 407, 116419.	0.3	18
182	Differential effects on blood and cerebrospinal fluid immune protein markers and kynurenine pathway metabolites from aerobic physical exercise in healthy subjects. Scientific Reports, 2021, 11, 1669.	1.6	18
183	Correlation between leukocyte phenotypes and prognosis of amyotrophic lateral sclerosis. ELife, 2022, 11, .	2.8	18
184	Facial nerve lesion response; strain differences but no involvement of IFN-Î³, STAT4 or STAT6. NeuroReport, 2002, 13, 1589-1593.	0.6	17
185	T-cell activation and HLA-regulated response to smoking in the deep airways of patients with multiple sclerosis. Clinical Immunology, 2016, 169, 114-120.	1.4	17
186	The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations. European Journal of Clinical Pharmacology, 2018, 74, 663-670.	0.8	17
187	Quantification of Plasma Kynurenine Metabolites Following One Bout of Sprint Interval Exercise. International Journal of Tryptophan Research, 2020, 13, 117864692097824.	1.0	17
188	Reappearance of calcitonin gene-related peptide-like immunoreactivity in the dorsal horn in long-term dorsal root transected rat. Brain Research, 1992, 585, 400-404.	1.1	16
189	Genetic dissection of neurodegeneration and CNS inflammation. Journal of the Neurological Sciences, 2005, 233, 99-108.	0.3	16
190	Genetically determined susceptibility to neurodegeneration is associated with expression of inflammatory genes. Neurobiology of Disease, 2006, 24, 67-88.	2.1	16
191	Retinal nerve fiber layer thickness associates with cognitive impairment and physical disability in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 36, 101414.	0.9	16
192	Epilepsy in systemic lupus erythematosus: prevalence and risk factors. European Journal of Neurology, 2020, 27, 297-307.	1.7	16
193	Absence of Neuronal Autoantibodies in Neuropsychiatric Systemic Lupus Erythematosus. Annals of Neurology, 2020, 88, 1244-1250.	2.8	16
194	Diagnostic accuracy of intrathecal kappa free light chains compared with OCBs in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e775.	3.1	16
195	Associations between autoimmune diseases and amyotrophic lateral sclerosis: a register-based study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 211-219.	1.1	16
196	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. Multiple Sclerosis Journal, 2022, 28, 1424-1456.	1.4	16
197	Small noncoding RNA profiling across cellular and biofluid compartments and their implications for multiple sclerosis immunopathology. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	15
198	Assessing the Preanalytical Variability of Plasma and Cerebrospinal Fluid Processing and Its Effects on Inflammation-Related Protein Biomarkers. Molecular and Cellular Proteomics, 2021, 20, 100157.	2.5	15

#	Article	IF	Citations
199	Association of Infectious Mononucleosis in Childhood and Adolescence With Risk for a Subsequent Multiple Sclerosis Diagnosis Among Siblings. JAMA Network Open, 2021, 4, e2124932.	2.8	15
200	Recovery from spinal cord injury differs between rat strains in a major histocompatibility complexâ€independent manner. European Journal of Neuroscience, 2007, 26, 1118-1127.	1.2	13
201	Identification of gene regions regulating inflammatory microglial response in the rat CNS after nerve injury. Journal of Neuroimmunology, 2009, 212, 82-92.	1.1	13
202	Inflammation and susceptibility to neurodegeneration: The use of unbiased genetics to decipher critical regulatory pathways. Neuroscience, 2009, 158, 1143-1150.	1.1	13
203	iNOS-mediated secondary inflammatory response differs between rat strains following experimental brain contusion. Acta Neurochirurgica, 2012, 154, 689-697.	0.9	13
204	Non-parametric combination analysis of multiple data types enables detection of novel regulatory mechanisms in T cells of multiple sclerosis patients. Scientific Reports, 2019, 9, 11996.	1.6	13
205	A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732096450.	0.5	13
206	Deep Learning Corpus Callosum Segmentation as a Neurodegenerative Marker in Multiple Sclerosis. Journal of Neuroimaging, 2021, 31, 493-500.	1.0	13
207	Influence of Perineurial Cells and Toll-Like Receptors 2 and 9 on Herpes simplex Type 1 Entry to the Central Nervous System in Rat Encephalitis. PLoS ONE, 2010, 5, e12350.	1.1	13
208	Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. Multiple Sclerosis Journal, 2022, 28, 842-846.	1.4	13
209	Bâ€cell repopulation dynamics and drug pharmacokinetics impact <scp>SARSâ€CoV</scp>â€2 vaccine efficacy in <scp>antiâ€CD20</scp>â€treated multiple sclerosis patients. European Journal of Neurology, 2022, 29, 3317-3328.	1.7	13
210	Host strain-dependent difference in susceptibility in a rat model of herpes simplex type 1 encephalitis. Journal of NeuroVirology, 2008, 14, 102-118.	1.0	12
211	The Calcitonin Receptor Gene Is a Candidate for Regulation of Susceptibility to Herpes simplex Type 1 Neuronal Infection Leading to Encephalitis in Rat. PLoS Pathogens, 2012, 8, e1002753.	2.1	12
212	Naturally Occurring Genetic Variability in Expression of Gsta4 is Associated with Differential Survival of Axotomized Rat Motoneurons. NeuroMolecular Medicine, 2012, 14, 15-29.	1.8	12
213	The association between multiple sclerosis and pain medications. Pain, 2019, 160, 424-432.	2.0	12
214	Neurodegeneration and glial activation patterns after mechanical nerve injury are differentially regulated by non-MHC genes in congenic inbred rat strains. Journal of Comparative Neurology, 2001, 431, 75-87.	0.9	12
215	Dynamics of extracellular matrix proteins in cerebrospinal fluid and serum and their relation to clinical outcome in human traumatic brain injury. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1565-1573.	1.4	11
216	Hospital-diagnosed infections before age 20 and risk of a subsequent multiple sclerosis diagnosis. Brain, 2021, 144, 2390-2400.	3.7	11

#	Article	IF	Citations
217	Genetic Regulation of Nerve Avulsionâ€Induced Spinal Cord Inflammation. Annals of the New York Academy of Sciences, 2000, 917, 186-196.	1.8	10
218	Variability in the CIITA gene interacts with HLA in multiple sclerosis. Genes and Immunity, 2014, 15, 162-167.	2.2	10
219	miRâ€31 regulates energy metabolism and is suppressed in TÂcells from patients with SjÃ¶gren's syndrome. European Journal of Immunology, 2019, 49, 313-322.	1.6	10
220	Expression of the phosphoinositide-specific phospholipase CÎ²3 gene in the rat. NeuroReport, 1995, 6, 2542-2544.	0.6	9
221	Genetic variability in the rat Aplec C-type lectin gene cluster regulates lymphocyte trafficking and motor neuron survival after traumatic nerve root injury. Journal of Neuroinflammation, 2013, 10, 60.	3.1	9
222	Unbiased Expression Mapping Identifies a Link between the Complement and Cholinergic Systems in the Rat Central Nervous System. Journal of Immunology, 2014, 192, 1138-1153.	0.4	9
223	Complement receptor 2 is up regulated in the spinal cord following nerve root injury and modulates the spinal cord response. Journal of Neuroinflammation, 2015, 12, 192.	3.1	9
224	Cognitive function did not improve after initiation of natalizumab treatment in relapsing-remitting multiple sclerosis. A prospective one-year dual control group study. Multiple Sclerosis and Related Disorders, 2016, 10, 36-43.	0.9	9
225	Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis â€“ Yes. Multiple Sclerosis Journal, 2018, 24, 1157-1159.	1.4	9
226	Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis. Neurology, 2021, 96, e1574-e1584.	1.5	9
227	Plasma bilirubin levels are reduced in first-episode psychosis patients and associates to working memory and duration of untreated psychosis. Scientific Reports, 2021, 11, 7527.	1.6	9
228	Susceptibility to Oxidative Stress Is Determined by Genetic Background in Neuronal Cell Cultures. ENeuro, 2018, 5, ENEURO.0335-17.2018.	0.9	9
229	The Karolinska NeuroCOVID study protocol: Neurocognitive impairment, biomarkers and advanced imaging in critical care survivors. Acta Anaesthesiologica Scandinavica, 2022, , .	0.7	9
230	Elevated endogenous GDNF induces altered dopamine signalling in mice and correlates with clinical severity in schizophrenia. Molecular Psychiatry, 2022, 27, 3247-3261.	4.1	9
231	Sequence and Expression of the Mouse Homologue to Human Phospholipase C Î²3 Neighboring Gene. Biochemical and Biophysical Research Communications, 1996, 223, 335-340.	1.0	8
232	Fine Mapping of Gene Regions Regulating Neurodegeneration. PLoS ONE, 2009, 4, e5906.	1.1	8
233	A minimal unified model of disease trajectories captures hallmarks of multiple sclerosis. Mathematical Biosciences, 2017, 289, 1-8.	0.9	8
234	Cerebrospinal fluid levels of sphingolipids associate with disease severity in first episode psychosis patients. Schizophrenia Research, 2018, 199, 438-441.	1.1	8

#	Article	IF	Citations
235	Increased peripheral levels of TARC/CCL17 in first episode psychosis patients. Schizophrenia Research, 2019, 210, 221-227.	1.1	8
236	Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MS. Multiple Sclerosis Journal, 2020, 26, 1532-1539.	1.4	8
237	Characterization of More Selective Central Nervous System Nrf2-Activating Novel Vinyl SulfoximineÂCompounds Compared to Dimethyl Fumarate. Neurotherapeutics, 2020, 17, 1142-1152.	2.1	8
238	Cerebrospinal fluid brevican and neurocan fragment patterns in human traumatic brain injury. Clinica Chimica Acta, 2021, 512, 74-83.	0.5	8
239	Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis. Multiple Sclerosis and Related Disorders, 2022, 57, 103385.	0.9	8
240	MRIâ€Based Manual versus Automated Corpus Callosum Volumetric Measurements in Multiple Sclerosis. Journal of Neuroimaging, 2020, 30, 198-204.	1.0	6
241	Effect of Vitamin D on Experimental Autoimmune Neuroinflammation Is Dependent on Haplotypes Comprising Naturally Occurring Allelic Variants of CIITA (Mhc2ta). Frontiers in Neurology, 2020, 11, 600401.	1.1	6
242	Reduction of the risk of PML in natalizumab treated MS patients in Sweden: An effect of improved PML risk surveillance. Multiple Sclerosis and Related Disorders, 2021, 50, 102842.	0.9	6
243	Is a Cancer Diagnosis Associated with Subsequent Risk of Transient Global Amnesia?. PLoS ONE, 2015, 10, e0122960.	1.1	6
244	Identification of cerebrospinal fluid and serum metabolomic biomarkers in first episode psychosis patients. Translational Psychiatry, 2022, 12, .	2.4	6
245	Both MHC and non-MHC genes regulate development of experimental neuropathic pain in rats. Neuroscience Letters, 2008, 442, 284-286.	1.0	5
246	Differential nerve injury-induced expression of MHC class II in the mouse correlates to genetic variability in the type I promoter of C2ta. Journal of Neuroimmunology, 2009, 212, 44-52.	1.1	5
247	Inflammatory and haemostatic markers in idiopathic intracranial hypertension. Journal of Internal Medicine, 2011, 270, 496-499.	2.7	5
248	Morvanâ€™s syndrome treated successfully with rituximab and lacosamide. BMJ Case Reports, 2019, 12, e226832.	0.2	5
249	Reply to: New Meta- and Mega-analyses of Magnetic Resonance Imaging Findings in Schizophrenia: Do They Really Increase Our Knowledge About the Nature of the Disease Process?. Biological Psychiatry, 2019, 85, e35-e39.	0.7	5
250	CSF levels of synaptosomal-associated protein 25 and synaptotagmin-1 in first-episode psychosis subjects. IBRO Reports, 2020, 8, 136-142.	0.3	5
251	Risk of depression in multiple sclerosis across disease-modifying therapies. Multiple Sclerosis Journal, 2022, 28, 632-641.	1.4	5
252	ALS patients with concurrent neuroinflammatory disorders; a nationwide clinical records study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 209-219.	1.1	5

#	Article	IF	Citations
253	Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden. JAMA Network Open, 2021, 4, e2136697.	2.8	5
254	Automatic deep learning multicontrast corpus callosum segmentation in multiple sclerosis. Journal of Neuroimaging, 2022, 32, 459-470.	1.0	5
255	Differential expression of multiple alternative spliceforms of the Men1 tumor suppressor gene in mouse. International Journal of Molecular Medicine, 2001, 8, 681-9.	1.8	5
256	The axon reaction: Identifying the genes that make a difference. Physiology and Behavior, 2007, 92, 67-74.	1.0	4
257	Effects of C2ta genetic polymorphisms on <scp>MHC</scp> class <scp>II</scp> expression and autoimmune diseases. Immunology, 2017, 150, 408-417.	2.0	4
258	Demyelinating events following antiâ€tumor necrosis factor alpha therapy: Rare but challenging to treat. European Journal of Neurology, 2022, 29, 2047-2055.	1.7	4
259	MicroRNAs as promising novel biomarkers and potential drug targets for inflammatory neurological diseases. Journal of the Neurological Sciences, 2015, 356, 3-4.	0.3	3
260	Successful combined treatment with thymectomy, rituximab and tocilizumab for severe thymoma-associated multi autoimmune syndrome. Journal of Neuroimmunology, 2019, 336, 577028.	1.1	3
261	Non-infectious comorbidity in patients with multiple sclerosis: A national cohort study in Sweden. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732094776.	0.5	3
262	Autologous Hematopoietic Stem Cell Transplantation In Neuromyelitis Optica: A Retrospective Study Of The EBMT Autoimmune Diseases Working Party In Collaboration With The University Of Sao Paulo, Ribeirao Preto, Brazil. Blood, 2013, 122, 2125-2125.	0.6	3
263	The Immunobiology of Multiple Sclerosis. , 2016, , 180-191.		2
264	Neurofilament light chain as a marker for cortical atrophy in multiple sclerosis without radiological signs of disease activity. Journal of Internal Medicine, 2021, 290, 473-476.	2.7	2
265	Neurodegeneration and glial activation patterns after mechanical nerve injury are differentially regulated by nonâ€MHC genes in congenic inbred rat strains. Journal of Comparative Neurology, 2001, 431, 75-87.	0.9	2
266	No Evidence for Disease History as a Risk Factor for Narcolepsy after A(H1N1)pdm09 Vaccination. PLoS ONE, 2016, 11, e0154296.	1.1	2
267	Molecular characterization of human and murine C11orf5, a new member of the FAUNA gene cluster. Mammalian Genome, 2000, 11, 78-80.	1.0	1
268	Low-dose rituximab should be used for treating MS in resource-limited settings: Yes. Multiple Sclerosis Journal, 2022, 28, 1028-1029.	1.4	1
269	Strain dependent differences in the inflammatory response to mechanical nerve injuries. Journal of Neuroimmunology, 1998, 90, 30.	1.1	0
270	Mapping of the human Ca2+ channel Î²4 subunit to 2q22-23 and its expression in developing mouse. Mammalian Genome, 1998, 9, 310-311.	1.0	0

#	Article	IF	Citations
271	200 THE MAJOR HISTOCOMPATIBILITY COMPLEX INFLUENCES NEUROPATHIC PAIN-LIKE BEHAVIORS IN RATS AFTER SCIATIC NERVE ISCHEMIC INJURY. European Journal of Pain, 2006, 10, S55-S55.	1.4	0
272	The DQB1(*)03:02 HLA haplotype is associated with increased risk of chronic pain after inguinal hernia surgery and lumbar disc herniation. Scandinavian Journal of Pain, 2013, 4, 258-258.	0.5	0
273	Methylome characterization of CD4+ T cells in multiple sclerosis â€" Establishing a role for miR-21 in autoimmune disease. Journal of Neuroimmunology, 2014, 275, 112.	1.1	0
274	High-intensity resistance training in multiple sclerosisâ€"an exploratory study. Physiotherapy, 2015, 101, e747.	0.2	0
275	Reply. Annals of Neurology, 2016, 80, 791-792.	2.8	0
276	Multiple Sclerosisâ€"A Tuning Fork Still Required. JAMA Neurology, 2017, 74, 264.	4.5	0
277	1633â€...Linear- versus conformational-protein directed autoantibodies in neuropsychiatric systemic lupus erythematosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A10.1-A10.	0.9	0
278	The DQB1*03:02 Genotype and Treatment for Pain in People With and Without Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 993.	1.1	0
279	Is the treatment of myasthenia gravis improving?. Neurology, 2020, 95, 509-510.	1.5	0
280	Neuroâ€COVID: Does severe COVIDâ€19 infection increase the risk for cognitive impairment?. Alzheimer's and Dementia, 2021, 17, .	0.4	0